OBJECTIVES: To establish an evidence-based cutoff to differentiate between early and late recurrence and to compare clinicopathologic risk factors between the two groups. SUMMARY BACKGROUND DATA: A clear definition of "early recurrence" after pancreatic ductal adenocarcinoma resection is currently lacking. METHODS: Patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma between 2000 and 2013 were included. Exclusion criteria were neoadjuvant therapy and incomplete follow-up. A minimum P-value approach was used to evaluate the optimal cut-off value of recurrence-free survival to divide the patients into early and late recurrence cohorts based on subsequent prognosis. Potential risk factors for early recurrence were assessed with logistic regression models. RESULTS: Of 957 included patients, 204 (21.3%) were recurrence-free at last follow-up. The optimal length of recurrence-free survival to distinguish between early (n = 388, 51.5%) and late recurrence (n = 365, 48.5%) was 12 months (P < 0.001). Patients with early recurrence had 1-, and 2-year post-recurrence survival rates of 20 and 6% compared with 45 and 22% for the late recurrence group (both P < 0.001). Preoperative risk factors for early recurrence included a Charlson age-comorbidity index ≥4 (OR 1.65), tumor size > 3.0 cm on computed tomography (OR 1.53) and CA 19-9 > 210 U/mL (OR 2.30). Postoperative risk factors consisted of poor tumor differentiation grade (OR 1.66), microscopic lymphovascular invasion (OR 1.70), a lymph node ratio > 0.2 (OR 2.49), and CA 19-9 > 37 U/mL (OR 3.38). Adjuvant chemotherapy (OR 0.28) and chemoradiotherapy (OR 0.29) were associated with a reduced likelihood of early recurrence. CONCLUSION: A recurrence-free interval of 12 months is the optimal threshold for differentiating between early and late recurrence, based on subsequent prognosis.
OBJECTIVES: To establish an evidence-based cutoff to differentiate between early and late recurrence and to compare clinicopathologic risk factors between the two groups. SUMMARY BACKGROUND DATA: A clear definition of "early recurrence" after pancreatic ductal adenocarcinoma resection is currently lacking. METHODS: Patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma between 2000 and 2013 were included. Exclusion criteria were neoadjuvant therapy and incomplete follow-up. A minimum P-value approach was used to evaluate the optimal cut-off value of recurrence-free survival to divide the patients into early and late recurrence cohorts based on subsequent prognosis. Potential risk factors for early recurrence were assessed with logistic regression models. RESULTS: Of 957 included patients, 204 (21.3%) were recurrence-free at last follow-up. The optimal length of recurrence-free survival to distinguish between early (n = 388, 51.5%) and late recurrence (n = 365, 48.5%) was 12 months (P < 0.001). Patients with early recurrence had 1-, and 2-year post-recurrence survival rates of 20 and 6% compared with 45 and 22% for the late recurrence group (both P < 0.001). Preoperative risk factors for early recurrence included a Charlson age-comorbidity index ≥4 (OR 1.65), tumor size > 3.0 cm on computed tomography (OR 1.53) and CA 19-9 > 210 U/mL (OR 2.30). Postoperative risk factors consisted of poor tumor differentiation grade (OR 1.66), microscopic lymphovascular invasion (OR 1.70), a lymph node ratio > 0.2 (OR 2.49), and CA 19-9 > 37 U/mL (OR 3.38). Adjuvant chemotherapy (OR 0.28) and chemoradiotherapy (OR 0.29) were associated with a reduced likelihood of early recurrence. CONCLUSION: A recurrence-free interval of 12 months is the optimal threshold for differentiating between early and late recurrence, based on subsequent prognosis.
Authors: Joshua G Barton; John P Bois; Michael G Sarr; Christina M Wood; Rui Qin; Kristine M Thomsen; Michael L Kendrick; Michael B Farnell Journal: J Gastrointest Surg Date: 2009-09-09 Impact factor: 3.452
Authors: Lois A Daamen; Vincent P Groot; Hanne D Heerkens; Martijn P W Intven; Hjalmar C van Santvoort; I Quintus Molenaar Journal: HPB (Oxford) Date: 2018-02-01 Impact factor: 3.647
Authors: Joshua D Cohen; Ammar A Javed; Christopher Thoburn; Fay Wong; Jeanne Tie; Peter Gibbs; C Max Schmidt; Michele T Yip-Schneider; Peter J Allen; Mark Schattner; Randall E Brand; Aatur D Singhi; Gloria M Petersen; Seung-Mo Hong; Song Cheol Kim; Massimo Falconi; Claudio Doglioni; Matthew J Weiss; Nita Ahuja; Jin He; Martin A Makary; Anirban Maitra; Samir M Hanash; Marco Dal Molin; Yuxuan Wang; Lu Li; Janine Ptak; Lisa Dobbyn; Joy Schaefer; Natalie Silliman; Maria Popoli; Michael G Goggins; Ralph H Hruban; Christopher L Wolfgang; Alison P Klein; Cristian Tomasetti; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Anne Marie Lennon Journal: Proc Natl Acad Sci U S A Date: 2017-09-05 Impact factor: 11.205
Authors: Daniela Dias-Santos; Cristina R Ferrone; Hui Zheng; Keith D Lillemoe; Carlos Fernández-Del Castillo Journal: Surgery Date: 2015-02-20 Impact factor: 3.982
Authors: Wenchuan Wu; Jin He; John L Cameron; Martin Makary; Kevin Soares; Nita Ahuja; Neda Rezaee; Joseph Herman; Lei Zheng; Daniel Laheru; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss Journal: Ann Surg Oncol Date: 2014-04-26 Impact factor: 5.344
Authors: Marco Niedergethmann; Ralf Hildenbrand; Birgit Wostbrock; Mark Hartel; Jörg W Sturm; Axel Richter; Stefan Post Journal: Pancreas Date: 2002-08 Impact factor: 3.327
Authors: Michele Reni; Stefano Cereda; Gianpaolo Balzano; Paolo Passoni; Alessia Rognone; Clara Fugazza; Elena Mazza; Alessandro Zerbi; Valerio Di Carlo; Eugenio Villa Journal: Cancer Date: 2009-06-15 Impact factor: 6.860
Authors: Brian A Boone; Herbert J Zeh; Brady K Mock; Paul J Johnson; Igor Dvorchik; Ken Lee; A James Moser; David L Bartlett; J Wallis Marsh Journal: HPB (Oxford) Date: 2013-04-22 Impact factor: 3.647